Products, and open for contract manufacturing: The Digest’s 2017 Multi-Slide Guide to REG Life Sciences

In January 2014, REG acquired LS9 for a purchase price of up to $61.5 million. Most of the old LS9 team, including the entire R&D leadership group, joined the newly named REG Life Sciences, LLC. The technology has been substantially developed under REG’s management, with several molecules ready for commercialization in the next 2-3 years — as we saw in this recent investor presentation on the unit’s progress.

REG’s Eric Bowen gave this illuminating overview of the division, its promise, progress and milestones to come at ABLC 2017 in Washington DC.